Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA.
Pediatr Blood Cancer. 2012 Nov;59(5):780-4. doi: 10.1002/pbc.24214. Epub 2012 May 30.
Systematic histopathologic examination of hepatoblastoma specimens from patients enrolled in therapeutic protocols has allowed the identification of clinically relevant histologic subtypes that are being incorporated into risk stratification systems. Genetic and molecular studies have documented recurrent chromosomal abnormalities and aberrant activation of developmental, and oncogenic signaling pathways in hepatoblastoma. Molecular profiling has also identified molecular subclasses and gene signatures that could be used to stratify hepatoblastoma patients. Future international collaboration is needed to develop consensus pathology classifications, and to progressively incorporate genetic and molecular biomarkers into therapeutic pediatric liver tumors protocols.
对入组治疗方案的肝母细胞瘤患者标本进行系统的组织病理学检查，有助于确定将纳入危险分层系统的临床相关组织学亚型。遗传学和分子研究已经证明肝母细胞瘤中存在反复出现的染色体异常和发育及致癌信号通路的异常激活。分子分析还确定了可用于对肝母细胞瘤患者进行分层的分子亚类和基因特征。需要未来开展国际合作，制定共识病理学分类，并将遗传和分子生物标志物逐步纳入小儿肝肿瘤治疗方案。
